Vertex Pharmaceuticals Incorporated (VRTX) EV/Sales Ratio: 9.02x
Is Vertex Pharmaceuticals Incorporated’s EV/Sales ratio high or low?
Vertex Pharmaceuticals Incorporated's EV/Sales ratio of 9.02x is in line with its 5-year average of 9.07x, around the middle of its 5-year range (5.85x–12.36x).
As of Sunday, June 14, 2026. 4.34% below its 12-month average of 9.43x.
VRTX EV/Sales Ratio Chart
VRTX Average EV/Sales Ratio Chart
VRTX Current vs Average EV/Sales Ratio Chart
VRTX EV/Sales Ratio Metrics
EV/SALES RATIO
9.02x
EV/SALES RATIO AVG TTM
9.43x
EV/SALES RATIO AVG 3Y
10.00x
EV/SALES RATIO AVG 5Y
9.07x
EV/SALES RATIO AVG 10Y
11.62x
EV/SALES RATIO AVG 15Y
15.29x
EV/SALES RATIO AVG 20Y
20.55x
CURRENT VS TTM AVG
-4.34%
CURRENT VS 3Y AVG
-9.77%
CURRENT VS 5Y AVG
-0.54%
CURRENT VS 10Y AVG
-22.37%
CURRENT VS 15Y AVG
-41.00%
CURRENT VS 20Y AVG
-56.11%
VRTX Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated (VRTX) | $112.92B | 9.02x | 9.43x | 10.00x | 9.07x |
| Bristol-Myers Squibb Company (BMY) | $116.66B | 3.13x | 2.99x | 3.12x | 3.47x |
| Medtronic plc (MDT) | $102.97B | 3.44x | 4.21x | 4.19x | 4.55x |
| Danaher Corporation (DHR) | $127.47B | 5.69x | 6.62x | 7.16x | 6.99x |
| CVS Health Corporation (CVS) | $130.09B | 0.49x | 0.44x | 0.43x | 0.51x |
| Elevance Health Inc. (ELV) | $87.75B | 0.56x | 0.51x | 0.67x | 0.76x |
| Intuitive Surgical, Inc. (ISRG) | $145.58B | 13.78x | 18.37x | 19.51x | 18.68x |
| Cigna Corporation (CI) | $78.83B | 0.37x | 0.38x | 0.50x | 0.55x |
| Pfizer Inc. (PFE) | $149.38B | 3.36x | 3.30x | 3.43x | 3.63x |
| Abbott Laboratories (ABT) | $153.59B | 4.02x | 4.93x | 5.00x | 4.98x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Vertex Pharmaceuticals Incorporated EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Vertex Pharmaceuticals Incorporated EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The EV/Sales ratio for VRTX stock is 9.02x.
- Is Vertex Pharmaceuticals Incorporated's EV/Sales ratio high or low?
- Vertex Pharmaceuticals Incorporated's EV/Sales ratio of 9.02x is in line with its 5-year average of 9.07x, around the middle of its 5-year range (5.85x–12.36x).
- What is the TTM average EV/Sales ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The TTM average EV/Sales ratio for VRTX stock is 9.43x.
- What is the 3Y average EV/Sales ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 3Y average EV/Sales ratio for VRTX stock is 10.00x.
- What is the 5Y average EV/Sales ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 5Y average EV/Sales ratio for VRTX stock is 9.07x.
- What is the 10Y average EV/Sales ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 10Y average EV/Sales ratio for VRTX stock is 11.62x.
- What is the 15Y average EV/Sales ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 15Y average EV/Sales ratio for VRTX stock is 15.29x.
- What is the 20Y average EV/Sales ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 20Y average EV/Sales ratio for VRTX stock is 20.55x.
Vertex Pharmaceuticals Incorporated EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-12 | 9.02x |
| 2026-06-11 | 9.02x |
| 2026-06-10 | 8.83x |
| 2026-06-09 | 9.04x |
| 2026-06-08 | 8.98x |
| 2026-06-05 | 9.06x |
| 2026-06-04 | 8.95x |
| 2026-06-03 | 8.67x |
| 2026-06-02 | 8.60x |
| 2026-06-01 | 8.88x |
| 2026-05-29 | 9.07x |
| 2026-05-28 | 9.08x |
| 2026-05-27 | 8.86x |
| 2026-05-26 | 8.83x |
| 2026-05-22 | 8.80x |
| 2026-05-21 | 8.78x |
| 2026-05-20 | 8.72x |
| 2026-05-19 | 8.80x |
| 2026-05-18 | 8.84x |
| 2026-05-15 | 8.85x |
| 2026-05-14 | 9.13x |
| 2026-05-13 | 9.19x |
| 2026-05-12 | 9.09x |
| 2026-05-11 | 8.81x |
| 2026-05-08 | 8.70x |
| 2026-05-07 | 8.60x |
| 2026-05-06 | 8.66x |
| 2026-05-05 | 8.59x |
| 2026-05-04 | 9.04x |
| 2026-05-01 | 8.92x |
| 2026-04-30 | 8.99x |
| 2026-04-29 | 8.90x |
| 2026-04-28 | 9.05x |
| 2026-04-27 | 8.96x |
| 2026-04-24 | 9.05x |
| 2026-04-23 | 9.16x |
| 2026-04-22 | 9.21x |
| 2026-04-21 | 9.19x |
| 2026-04-20 | 9.24x |
| 2026-04-17 | 9.29x |
| 2026-04-16 | 9.17x |
| 2026-04-15 | 9.30x |
| 2026-04-14 | 9.35x |
| 2026-04-13 | 9.26x |
| 2026-04-10 | 9.18x |
| 2026-04-09 | 9.40x |
| 2026-04-08 | 9.34x |
| 2026-04-07 | 9.09x |
| 2026-04-06 | 9.14x |
| 2026-04-02 | 9.23x |
| 2026-04-01 | 9.41x |
| 2026-03-31 | 9.40x |
| 2026-03-30 | 9.33x |
| 2026-03-27 | 9.11x |
| 2026-03-26 | 9.55x |
| 2026-03-25 | 9.58x |
| 2026-03-24 | 9.44x |
| 2026-03-23 | 9.50x |
| 2026-03-20 | 9.56x |
| 2026-03-19 | 9.64x |
| 2026-03-18 | 9.51x |
| 2026-03-17 | 9.74x |
| 2026-03-16 | 9.82x |
| 2026-03-13 | 9.88x |
| 2026-03-12 | 10.07x |
| 2026-03-11 | 10.37x |
| 2026-03-10 | 10.52x |
| 2026-03-09 | 9.70x |
| 2026-03-06 | 9.62x |
| 2026-03-05 | 9.70x |
| 2026-03-04 | 10.07x |
| 2026-03-03 | 9.99x |
| 2026-03-02 | 10.24x |
| 2026-02-27 | 10.47x |
| 2026-02-26 | 10.11x |
| 2026-02-25 | 10.18x |
| 2026-02-24 | 10.27x |
| 2026-02-23 | 10.13x |
| 2026-02-20 | 10.05x |
| 2026-02-19 | 9.88x |
| 2026-02-18 | 9.91x |
| 2026-02-17 | 10.05x |
| 2026-02-13 | 10.36x |
| 2026-02-12 | 9.95x |
| 2026-02-11 | 9.87x |
| 2026-02-10 | 9.92x |
| 2026-02-09 | 10.08x |
| 2026-02-06 | 10.24x |
| 2026-02-05 | 9.82x |
| 2026-02-04 | 10.07x |
| 2026-02-03 | 9.97x |
| 2026-02-02 | 10.11x |
| 2026-01-30 | 10.06x |
| 2026-01-29 | 10.19x |
| 2026-01-28 | 10.24x |
| 2026-01-27 | 10.15x |
| 2026-01-26 | 10.21x |
| 2026-01-23 | 10.03x |
| 2026-01-22 | 10.00x |
| 2026-01-21 | 9.87x |
| 2026-01-20 | 9.45x |
| 2026-01-16 | 9.43x |
| 2026-01-15 | 9.38x |
| 2026-01-14 | 9.61x |
| 2026-01-13 | 9.73x |
| 2026-01-12 | 9.86x |
| 2026-01-09 | 9.93x |
| 2026-01-08 | 10.06x |
| 2026-01-07 | 10.37x |
| 2026-01-06 | 10.03x |
| 2026-01-05 | 9.60x |
| 2026-01-02 | 9.67x |
| 2025-12-31 | 9.70x |
| 2025-12-30 | 9.71x |
| 2025-12-29 | 9.84x |
| 2025-12-26 | 9.91x |
| 2025-12-24 | 9.91x |
| 2025-12-23 | 9.83x |
| 2025-12-22 | 9.85x |
| 2025-12-19 | 9.76x |
| 2025-12-18 | 9.57x |
| 2025-12-17 | 9.61x |
| 2025-12-16 | 9.73x |
| 2025-12-15 | 9.75x |
| 2025-12-12 | 9.67x |
| 2025-12-11 | 9.53x |
| 2025-12-10 | 9.51x |
| 2025-12-09 | 9.34x |
| 2025-12-08 | 9.45x |
| 2025-12-05 | 9.74x |
| 2025-12-04 | 9.78x |
| 2025-12-03 | 9.91x |
| 2025-12-02 | 9.25x |
| 2025-12-01 | 9.09x |
| 2025-11-28 | 9.26x |
| 2025-11-26 | 9.23x |
| 2025-11-25 | 9.18x |
| 2025-11-24 | 9.05x |
| 2025-11-21 | 9.11x |
| 2025-11-20 | 9.01x |
| 2025-11-19 | 8.99x |
| 2025-11-18 | 9.30x |
| 2025-11-17 | 9.27x |
| 2025-11-14 | 9.34x |
| 2025-11-13 | 9.28x |
| 2025-11-12 | 9.28x |
| 2025-11-11 | 9.17x |
| 2025-11-10 | 8.99x |
| 2025-11-07 | 8.73x |
| 2025-11-06 | 8.88x |
| 2025-11-05 | 8.90x |
| 2025-11-04 | 9.00x |
| 2025-11-03 | 9.36x |
| 2025-10-31 | 9.35x |
| 2025-10-30 | 9.22x |
| 2025-10-29 | 9.16x |
| 2025-10-28 | 9.28x |
| 2025-10-27 | 9.22x |
| 2025-10-24 | 9.25x |
| 2025-10-23 | 9.28x |
| 2025-10-22 | 9.37x |
| 2025-10-21 | 9.36x |
| 2025-10-20 | 9.20x |
| 2025-10-17 | 9.15x |
| 2025-10-16 | 8.96x |
| 2025-10-15 | 8.95x |
| 2025-10-14 | 9.04x |
| 2025-10-13 | 8.93x |
| 2025-10-10 | 8.94x |
| 2025-10-09 | 9.10x |
| 2025-10-08 | 9.25x |
| 2025-10-07 | 9.00x |
| 2025-10-06 | 8.83x |
| 2025-10-03 | 8.84x |
| 2025-10-02 | 8.97x |
| 2025-10-01 | 8.86x |
| 2025-09-30 | 8.58x |
| 2025-09-29 | 8.66x |
| 2025-09-26 | 8.44x |
| 2025-09-25 | 8.36x |
| 2025-09-24 | 8.24x |
| 2025-09-23 | 8.31x |
| 2025-09-22 | 8.39x |
| 2025-09-19 | 8.38x |
| 2025-09-18 | 8.48x |
| 2025-09-17 | 8.48x |
| 2025-09-16 | 8.57x |
| 2025-09-15 | 8.61x |
| 2025-09-12 | 8.64x |
| 2025-09-11 | 8.71x |
| 2025-09-10 | 8.51x |
| 2025-09-09 | 8.69x |
| 2025-09-08 | 8.66x |
| 2025-09-05 | 8.68x |
| 2025-09-04 | 8.70x |
| 2025-09-03 | 8.69x |
| 2025-09-02 | 8.79x |
| 2025-08-29 | 8.56x |
| 2025-08-28 | 8.59x |
| 2025-08-27 | 8.52x |
| 2025-08-26 | 8.48x |
| 2025-08-25 | 8.52x |
| 2025-08-22 | 8.66x |
| 2025-08-21 | 8.71x |
| 2025-08-20 | 8.64x |
| 2025-08-19 | 8.56x |
| 2025-08-18 | 8.54x |
| 2025-08-15 | 8.60x |
| 2025-08-14 | 8.55x |
| 2025-08-13 | 8.68x |
| 2025-08-12 | 8.49x |
| 2025-08-11 | 8.19x |
| 2025-08-08 | 8.01x |
| 2025-08-07 | 8.22x |
| 2025-08-06 | 8.44x |
| 2025-08-05 | 8.20x |
| 2025-08-04 | 10.77x |
| 2025-08-01 | 10.53x |
| 2025-07-31 | 10.41x |
| 2025-07-30 | 10.70x |
| 2025-07-29 | 10.68x |
| 2025-07-28 | 10.50x |
| 2025-07-25 | 10.71x |
| 2025-07-24 | 10.77x |
| 2025-07-23 | 10.88x |
| 2025-07-22 | 10.72x |
| 2025-07-21 | 10.45x |
| 2025-07-18 | 10.48x |
| 2025-07-17 | 10.56x |
| 2025-07-16 | 10.71x |
| 2025-07-15 | 10.58x |
| 2025-07-14 | 10.77x |
| 2025-07-11 | 10.69x |
| 2025-07-10 | 10.94x |
| 2025-07-09 | 10.93x |
| 2025-07-08 | 10.63x |
| 2025-07-07 | 10.47x |
| 2025-07-03 | 10.47x |
| 2025-07-02 | 10.41x |
| 2025-07-01 | 10.30x |
| 2025-06-30 | 10.14x |
| 2025-06-27 | 10.04x |
| 2025-06-26 | 10.09x |
| 2025-06-25 | 10.15x |
| 2025-06-24 | 10.25x |
| 2025-06-23 | 10.10x |
| 2025-06-20 | 10.03x |
| 2025-06-18 | 10.21x |
| 2025-06-17 | 10.06x |
| 2025-06-16 | 10.27x |
| 2025-06-13 | 10.38x |
| 2025-06-12 | 10.48x |
| 2025-06-11 | 10.31x |
| 2025-06-10 | 10.28x |
| 2025-06-09 | 10.16x |
| 2025-06-06 | 10.26x |
| 2025-06-05 | 10.10x |
| 2025-06-04 | 10.15x |
| 2025-06-03 | 10.17x |
| 2025-06-02 | 10.14x |
Showing the most recent 260 of 5,033 data points. The chart above shows the full history.
Related Metrics
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani